NFKB1 and cancer: Another therapeutic approach for cancer-associated inflammation involves selectively suppressing crucial proinflammatory mediators, using blockers specifically targeting TNF-α (Hou et al., 2021), NF-κB (Shishodia et al., 2003; Capece et al., 2018), and COX-2 (Chatterjee et al., 2018).